Arvinas, Inc. Announces Exercise of Underwriters' Option to Purchase Additional Shares
[December 28, 2020] Arvinas, Inc. Announces Exercise of Underwriters' Option to Purchase Additional Shares NEW HAVEN, Conn., Dec. 28, 2020 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation using its PROTAC ® Discovery Engine, today announced that the underwriters of its previously announced underwritten public offering of common stock, which closed on December 18, 2020, have exercised in full their option to purchase additional shares of common stock at the public offering price, less...